GREY:IMVIF - Post by User
Comment by
europe10on Sep 27, 2019 12:38pm
125 Views
Post# 30171213
RE:RE:Real Value
RE:RE:Real ValueStock price tells us all. The entire worlds knowledge is in the stock price.
There is no way that the basket trial will be anything significant. At least not for the stock price.
IMV might have cash to 4Q 2020, at current burn rate, That burn rate will increase significantly and a financing MUST be done well in advance of IMV running out of money.
A financing latest 1Q next year is a must. If Merck loves IMV, it might be a deal with them including cash. Otherwise another PP (likely at a much lower price) is inevitable
I hope to be proven wrong!
My hope is:
Very good test results in the basket trials (the fact that IMV goes ahead adding another 184 patients could indicate that?)
Followed by either a decent deal with Merck, or a well planned and executed PP -- the opposite of the previous PP